Affibody, GE to collaborate on PET tracers

Biopharmaceutical company Affibody and GE Healthcare are collaborating to develop and bring to market Affibody's PET imaging tracers.

The company's ABY-025 is a HER2-detecting PET imaging tracer under clinical development, Affibody said. It is for use in diagnosing metastatic breast cancer, according to the firm.

Affibody is also developing PD-L1, a binding molecule that would be used to improve selection and monitoring of patients with immuno-oncology treatments, and will work with GE on clinical proof-of-concept studies.

Page 1 of 1252
Next Page